Reviva Pharmaceuticals Holdings, Inc. (RVPH)

USD 1.44

(2.5%)

Market Cap (In USD)

47.98 Million

Revenue (In USD)

-

Net Income (In USD)

-24.33 Million

Avg. Volume

481.64 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.6-5.67
PE
-
EPS
-
Beta Value
-0.055
ISIN
US76152G1004
CUSIP
76152G100
CIK
1742927
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Laxminarayan Bhat Ph.D.
Employee Count
-
Website
https://revivapharma.com
Ipo Date
2018-10-18
Details
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.